Details

Autor(en) / Beteiligte

• Zeuzem, Stefan
• Jacobson, Ira M
• Baykal, Tolga
• Marinho, Rui T
• Poordad, Fred
• Bourlière, Marc
• Sulkowski, Mark S
• Wedemeyer, Heiner
• Tam, Edward
• Desmond, Paul
• Jensen, Donald M
• Di Bisceglie, Adrian M
• Varunok, Peter
• Hassanein, Tarek
• Xiong, Junyuan
• Pilot-Matias, Tami
• DaSilva-Tillmann, Barbara
• Larsen, Lois
• Podsadecki, Thomas
• Bernstein, Barry

Titel

Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

Ist Teil von

• The New England journal of medicine, 2014-04, Vol.370 (17), p.1604-1614

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• In this trial in patients with HCV genotype 1 infection and no cirrhosis who had previously been treated with peginterferon and ribavirin, retreatment with three new oral antiviral agents and ribavirin resulted in a sustained virologic response in 96% of patients. Patients with chronic hepatitis C virus (HCV) infection are at risk for progressive liver fibrosis, cirrhosis, portal hypertension, hepatocellular carcinoma, and decompensated liver disease. HCV infection can be cured with antiviral therapy, reducing the risk of illness and death associated with end-stage liver disease. 1 – 3 For more than a decade, patients with HCV genotype 1 infection have been treated with peginterferon–ribavirin dual therapy, resulting in rates of sustained virologic response of approximately 40 to 50%. 4 – 6 Response rates among previously untreated patients have been shown to increase to 68 to 75% with peginterferon–ribavirin plus a protease inhibitor (telaprevir or boceprevir, . . .